227 related articles for article (PubMed ID: 15233732)
1. DNA vaccines against human immunodeficiency virus type 1.
Estcourt MJ; McMichael AJ; Hanke T
Immunol Rev; 2004 Jun; 199():144-55. PubMed ID: 15233732
[TBL] [Abstract][Full Text] [Related]
2. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.
Calarota SA; Weiner DB
Immunol Rev; 2004 Jun; 199():84-99. PubMed ID: 15233728
[TBL] [Abstract][Full Text] [Related]
4. New hope for an AIDS vaccine.
Robinson HL
Nat Rev Immunol; 2002 Apr; 2(4):239-50. PubMed ID: 12001995
[TBL] [Abstract][Full Text] [Related]
5. HIV/AIDS vaccines: 2007.
Robinson HL
Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
[TBL] [Abstract][Full Text] [Related]
6. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
7. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
[TBL] [Abstract][Full Text] [Related]
8. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
9. Prime-boost strategies in DNA vaccines.
Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
[TBL] [Abstract][Full Text] [Related]
10. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
Amara RR; Sharma S; Patel M; Smith JM; Chennareddi L; Herndon JG; Robinson HL
Virology; 2005 Mar; 334(1):124-33. PubMed ID: 15749128
[TBL] [Abstract][Full Text] [Related]
11. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
12. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.
Calarota SA; Weiner DB; Lori F; Lisziewicz J
Vaccine; 2007 Apr; 25(16):3070-4. PubMed ID: 17292518
[TBL] [Abstract][Full Text] [Related]
13. A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins.
Bazhan SI; Karpenko LI; Lebedev LR; Uzhachenko RV; Belavin PA; Eroshkin AM; Ilyichev AA
Mol Immunol; 2008 Feb; 45(3):661-9. PubMed ID: 17869341
[TBL] [Abstract][Full Text] [Related]
14. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
[TBL] [Abstract][Full Text] [Related]
15. Antigen presentation and related immunological aspects of HIV-1 vaccines.
Steinman RM; Germain RN
AIDS; 1998; 12 Suppl A():S97-112. PubMed ID: 9632991
[No Abstract] [Full Text] [Related]
16. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
Wingard JB; Anderson B; Weissman D
Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
19. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
Wang X; Uto T; Akagi T; Akashi M; Baba M
J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
[TBL] [Abstract][Full Text] [Related]
20. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
